Title: Novel biomarker algorithmic panel measuring permutations of immune response to cardiac endothelial injury and global risk factors identifies patients at risk of acute coronary syndrome (ACS)

Wednesday, March 9, 2016 12:00—1:00 Noon
Telecast: UC Irvine Douglas Hospital Radiology Conference Room 0117
Live: UC Irvine Campus Medical Education Building, Colloquium 3070

NOTE: Guest Speaker will be in Medical Education Colloquium 3070. Videocast will be in UCIMC Radiology Conference Room, Douglas Hospital Room 0117

Abstract:
Biomarkers of immune response to endothelial injury by free radicals identifies sub-clinical disease and can predict risk of an acute coronary syndrome (ACS).

About the Speaker: Dr. Douglas Harrington has over 25 years of experience in the research, development, commercialization, and expansion of innovative healthcare technology and services. Dr. Harrington was a member of one of the first heart transplant teams led by Dr. Jack Copeland from Stanford University. He co-founded one of the first clinical molecular biology laboratories in the U.S. with the Nebraska Lymphoma Study Group headed by Dr. Jim Armitage. As President and Lab Director of Nichols Institute, Dr. Harrington expanded their molecular genetics, infectious disease, immunology, cytogenetic, and anatomic pathology offerings. Dr. Harrington led the team that developed one of the first digital microscopes targeted at minimal residual disease and circulating tumor cells as the founder and CEO of Clarient. Dr. Harrington also led the turnaround and reinstatement of the Federal license of Specialty Laboratories, a New York Stock Exchange company, as CEO and Laboratory Director.

Dr. Harrington has developed patents for an automated method for image analysis of residual cancer cells, a patent covering catalytic heavy metal extraction, and a patent pending on biomarker assay for diagnosis and classification of cardiac disease. He has been involved as director or founder of multiple startup companies - from devices to molecular genetics focusing on immunology, cancer and cardiology, where he has taken a number of new molecular technologies through state and federal regulatory approval, and has been involved in the commercialization of over 200 academic discoveries. Throughout his career Dr. Harrington has remained a Clinical Professor of Pathology at the USC Keck School of medicine, a published author of numerous peer-reviewed papers, and a sought after speaker in the area of preventive medicine and technology development. In addition to being the CEO & Lab Director of Global Discovery Biosciences, Dr. Harrington received his BA in molecular biology, and MD from the University of Colorado Health Sciences Center and is board certified in hematology, anatomic and clinical pathology.